Fasudil
(5-Isoquinolinesulfonyl)homopiperazine, 2HCl White solid. A cell-permeable Ca2+ antagonist with anti-vasospastic properties. Inhibits protein kinase A (Ki = 1.6 µM), protein kinase G (Ki = 1.6 µM), and myosin light chain kinase (Ki = 36 µM). Also reported to potently inhibit Rho-associated kinase (ROCK; IC50 = 10.7 µM). Prevents apoptosis and enhances the survival and cloning efficiency of dissociated hES cells without affecting their pluripotency. Purity: ≥98% by HPLC. CAS 103745-39-7. Ref.: Watanabe, K., et al. 2007. Nature Biotech. 25, 681. Swärd, K., et al. 2000. J. Physiol. 522, 33. Takizawa, S., et al. 1993. Eur. J. Pharmacol. 250, 431. Seto, M., et al. 1991. Eur. J. Pharmacol. 195, 267. Shirotani, M., et al. 1991. J. Pharmacol. Exp. Ther. 259, 738. Asano, T., et al. 1990. Eur. J. Pharmacol. 190, 365. Sasaki, Y., and Sasaki, Y. 1990. Biochem. Biophys. Res. Commun. 171, 1182. Asano, T., et al. 1989. Br. J. Pharmacol. 98, 1091.
R: 20/21/22; S: 36 |
